News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Eliminating cancer with nivolumab and the chemotherapy regimen AVD – NCI
NCI/LinkedIn
Dec 26, 2024, 15:10

Eliminating cancer with nivolumab and the chemotherapy regimen AVD – NCI

National Cancer Institute (NCI) shared a post on LinkedIn:

“In a large clinical trial, treatment with nivolumab (Opdivo) and the chemotherapy regimen AVD was better at eliminating cancer and keeping it at bay than the current standard initial treatment for the disease, AVD and brentuximab (Adcetris). The nivolumab combination also had fewer side effects.

Media Description: An imaging scan of a man with advanced Hodgkin lymphoma, showing multiple areas with cancer (red and yellow-orange) throughout the upper body. Credit: Courtesy of Pranav Sharma, Radiopaedia.org. CC BY-NC-SA 3.0.”

Eliminating cancer with nivolumab and the chemotherapy regimen AVD - NCI

More posts featuring National Cancer Institute.

Adcetris brentuximab cancer Hodgkin lymphoma National Cancer Institute NCI nivolumab OncoDaily Oncology Opdivo
Special Coverage
Blog
Apr 15, 2025, 08:23
Stephen V Liu: Taletrectinib and zidesamtinib promise to move the field of ROS1 NSCLC by addressing resistance and safety
Positive
Apr 15, 2025, 08:03
Rawan Hammad: Thank you to the speakers, moderators, organizers and attendees who made SIOP Asia Riyadh 2025 a success!
Blog
Apr 15, 2025, 07:52
Basel Refky: Presenting in Lebanon, Masterclass in Cairo, and a Publication — A Tough Weekend but Fruitful
Blog
Apr 15, 2025, 07:52
Luchuo Engelbert Bain: The Future is bright - African medical students taking their future into their hands
Blog
Apr 15, 2025, 07:40
Estela Rodriguez: The second-line options for EGFR lung cancer beyond platinum-chemo after best therapies upfront
Blog
Apr 15, 2025, 07:23
EACR about their affiliated journal, Molecular Oncology
Blog
Apr 15, 2025, 07:21
Enrolling for the ComboMATCH Treatment Trial E5 - ECOG-ACRIN Cancer Research Group
Opinion
Apr 15, 2025, 07:10
The NCCN 2025 Breast Cancer Congress recorded presentations are now available
Blog
Apr 15, 2025, 07:09
Roberto Ferrara: Neoadjuvant versus perioperative chemo-immunotherapy according to pathological response in resectable NSCLC
Blog
Apr 15, 2025, 07:04
Imane Bensalim: Honored to have participated in Sim Africa 2025
Blog
Apr 15, 2025, 06:40
The application for the 2025 Ambassador Program is open - American Society of Hematology
Blog
Apr 15, 2025, 06:16
Applications for the ENYGO Introduction to Robotic Surgery Course close May 12 - ESGO